Drugs / VBC101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07136779 | Sep 2025 → Jul 2027 expected | — | VelaVigo Bio Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VBC101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07136779 ↗ |
| Target | EGFR | “VBC101, AN EGFR AND CMET TARGETED BI-SPECIFIC ANTIBODY DRUG CONJUGATE” NCT07136779 ↗ |
| Target | MET | “VBC101, AN EGFR AND CMET TARGETED BI-SPECIFIC ANTIBODY DRUG CONJUGATE” NCT07136779 ↗ |